HIV/AIDs presents significant treatment challenges due to increasing resistance to current antiretroviral drugs. This resistance is exacerbated in low- and middle-income countries due to drug misuse, inadequate drug supply, and poor treatment monitoring. Despite these challenges, there has been progress in developing new ARV drugs targeting various components of HIV. This review, updated as of […]
According to preliminary data, individuals with HIV who are not able to achieve viral suppression with oral treatments may benefit from long-acting injectable cabotegravir and rilpivirine (LA-CAB/RPV). Utilizing the Consolidated Framework for Implementation Research, a research conducted at Ward 86 in San Francisco examined patient, provider, and contextual characteristics that impact the implementation of LA-CAB/RPV.
The United States legalized the use of long-acting injectable pre-exposure prophylaxis for HIV prevention (LAI-PrEP) in 2021. However, little is known about how transgender and nonbinary young adults, a population that faces significant obstacles to HIV prevention, see LAI-PrEP. The study looks at this population’s perceptions of long-acting injectable PrEP’s acceptability, convenience, and efficacy compared
Five long-acting (LA) antiretrovirals (ARVs)—cabotegravir, rilpivirine, lenacapavir, ibalizumab, and dapivirine—are now available in a few countries for HIV-1 prevention and treatment. To integrate LA ARVs into routine clinical practice, significant changes in HIV-1 care are needed. Consensus recommendations will guide doctors in the effective and safe use of these new, complex agents. These guidelines aim
In the United States, HIV infections disproportionately afflict Latino men who have sex with men (LMSM). Pre-exposure prophylaxis, or PrEP, has not been widely adopted by LMSM as a means of preventing HIV. Injectable PrEP with a long half-life (LAI-PrEP) may help with behavioral, cognitive, and structural adherence difficulties. The purpose of our study was
Pre-exposure prophylaxis (PrEP) is one HIV preventive strategy that is widely used, yet AIDS cases still outnumber treatment and prevention attempts. Significant obstacles still exist, including stigma, prejudice, and lack of access, especially for vulnerable populations like women, minorities, and LGBTQ people. In order to address these problems through a comprehensive approach to sexual health
Early diagnosis, consistent treatment, and patient education are extremely important in managing HIV and preventing its spread. The article discusses the updated guidelines for treating and preventing HIV infection, focusing on the latest recommendations for antiretroviral therapy and preventive measures like pre-exposure prophylaxis (PrEP). The article also outlines strategies to enhance adherence to these guidelines
Reductions in HIV acquisition have slowed, and the global community is significantly off track from global goals. Oral pre-exposure prophylaxis (PrEP) alone cannot address the diverse needs of the millions of people at risk of HIV acquisition. Long-acting injectable cabotegravir (CAB-LA) received United States Food and Drug Administration approval for HIV prevention in December 2021.
WHO guidelines recommend daily oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) for pre-exposure prophylaxis (PrEP) of HIV in people at high risk of HIV infection. However, due to social, psychological and other reasons, the compliance with daily oral TDF-FTC in real life is low. Long-acting cabotegravir is currently the only long-acting drug approved by
CAB-LA is highly efficacious for HIV prevention with few safety concerns. CAB-LA may lead to an increased risk of INSTI resistance among those who have acute HIV infection at initiation or become infected while taking CAB-LA. However, results are limited to controlled studies; more research is needed on real-world implementation.
